

Mini-Symposium

New Technologies for Cancer Immunotherapy

Keynote Speakers:

Professor Alessandra Curioni Fontecedro (University of Fribourg, Switzerland)

Professor Sergio Quezada (University College London, United Kingdom)

Professor Christian Rolfo (Ohio State University, Columbus, OH, USA)

Moderator:

Professor Marco Donia (University of Copenhagen, Denmark)

Program:

12:45-12:50: Welcome and Introduction, Marco Donia

12:50-13:30: Next Wave of Cancer Immunotherapy, Alessandra Curioni Fontecedro

13:30-14:10: Development of New ImmunoTechnologies: collaboration between academia and industry, Sergio Quezada

14:10-14:20: Break

14:20-15:00: Liquid biopsy in Cancer Immunotherapy: present and future (remote lecture), Christian Rolfo

15:10-15:30: Panel Discussion (Curioni Fontecedro, Quezada, Rolfo, Moderator: Donia)

Friday April 11th 2025, 12:45-15:30 CET

Store Auditorium, Herlev Hospital, Herlev, Denmark

Borgmester Ib Juuls Vej 1, 2730 Herlev

No Registration Required

About the Symposium

Cancer immunotherapy has revolutionized the treatment of several solid tumor types, enabling long-term survival and even cures for some patients with metastatic disease. However, despite these advances, the majority of patients do not benefit from current immunotherapies, highlighting the urgent need for more effective treatment strategies and better monitoring methods.

This symposium will address these challenges and explore emerging innovations in cancer immunotherapy. Professor Alessandra Curioni-Fontecedro will present new immunotherapy strategies aimed at improving outcomes for patients with hard-to-treat tumors. Professor Sergio Quezada will discuss the development of novel immunotechnologies, emphasizing the importance of collaboration between academia and industry. Professor Christian Rolfo will provide insights into the latest advancements in liquid biopsy and its role in monitoring treatment response and disease progression.

Target audience: cancer researchers, clinicians, and industry professionals.

About the Keynote Speakers



Alessandra Curioni Fontecedro is a Professor of Oncology at the University of Fribourg, Switzerland, and the Head of Medical Oncology at the Hospital of Fribourg. She serves as the president of the Lung Cancer Working Group of the Swiss Group for Clinical Cancer Research (SAKK) and coordinates the Lung Cancer Program at the European School of Oncology (ESO). Her research focuses on developing combinatorial treatments and understanding their mechanisms of action in mesothelioma and lung cancer, aiming to establish new therapeutic approaches. More about Dr. Curioni Fontecedro at <https://www.unifr.ch/directory/en/people/362992/e71ee>



Sergio Quezada is a Professor of Cancer Immunology and Immunotherapy at University College London Cancer Institute. His work has been pivotal in developing anti-CD25 antibodies with Tusk Therapeutics and advancing cell therapies at Achilles Therapeutics. His research focuses on the tumor microenvironment, regulatory T cells, and immune checkpoint blockade, with an emphasis on translating findings into clinical applications. More about Dr. Quezada at <https://profiles.ucl.ac.uk/30714-sergio-quezada>



Christian Rolfo is a Professor of Oncology at Ohio State University, USA, and the Director of the Division of Medical Oncology and Associate Director for Early Phase Clinical Trials at the Arthur G. James Cancer Hospital and Solove Research Institute. He serves as the President of the International Society of Liquid Biopsy (ISLB). His research centers on liquid biopsies, focusing on non-invasive diagnostic tools that provide real-time monitoring of cancer evolution and treatment response. More about Dr. Rolfo at <https://www.esmo.org/about-esmo/biographies/christian-rolfo>.